Sentence examples for days on therapy from inspiring English sources

Among 65 and 94 patients identified before and after mecA PCR, respectively, vancomycin usage (measured in days on therapy) declined from a median of 3 days (range, 1 to 44 days) in the pre-PCR period to 1 day (range, 0 to 18 days) in the post-PCR period (P < 0.0001).

The median days on therapy was 16 (IQR 14 19) for IV catheter-related infections; 22 (IQR 15 40) for infections caused by other removable foci; 27 (IQR 15 46) for non-removable infections; and 16 (IQR 13 26) if the focus was not established.

Multiple comparisons across different days on therapy were adjusted conservatively by using Tukey adjustment.

Overall median days on therapy per cycle were 13 days during induction and 20 days during maintenance.

Progression-free survival (PFS) was defined as the number of days on therapy until therapy was discontinued because of disease progression, as documented in the patient's medical records.

Covariates used in the final propensity model were age, gender, sequential organ failure assessment (SOFA) score, RRT, fluid balance, vancomycin dose (mg/kg/24 h), infection source, and number of days on therapy.

These lab-based findings have also been supported by the observation that increased PI3K/AKT signalling occurs in some early (4 25 days) on-therapy specimens from patients treated with a BRAF inhibitor (Shi et al, 2014).

Three experimental setups were performed: (A) short-term effects of sunitinib (5 days of therapy) on tumor oxygenation, (B) long-term sunitinib therapy (14 days of therapy; 5 days on, 2 days off), and (C) treatment withdrawal (another 12 days after finishing therapy).

Laboratory adverse events occurred more frequently on days of therapy with ceftazidime than with cefepime (373 vs. 341 per 1000 infant days, P < 0.001).

Interestingly, most nonpersistent patients (56%) omitted treatment once during follow-up; among them, the number of therapy-discontinuation days was low (4% of the indicated days of therapy) but impacted negatively on the disease prognosis.

Viruses isolated from sequential specimens obtained at admission and three days later on therapy from one patient showed stable susceptibilities to oseltamivir (IC50 4.75 and 3.86 nM respectively).